
    
      This is a long-term prospective, observational post-marketing surveillance study of niraparib
      in participants with ovarian cancer (including fallopian tube, or primary peritoneal cancer)
      who are in complete or partial response to first-line platinum-based chemotherapy or who had
      complete or partial response to 2 or more lines of platinum-based chemotherapy or who have
      been treated with 3 or more prior chemotherapy regimens with either: BRCA mutation
      irrespective of platinum sensitivity; or platinum-sensitive HRD positive. The study will
      assess the safety and effectiveness of niraparib for its approved indication with real-world
      setting in South Korea.

      The study will enroll approximately 600 participants. The data will be collected
      prospectively at the study sites will be recorded into electronic case report forms (e-CRFs).
      All the participants will be assigned to a single observational cohort:

      â€¢ Participants With Ovarian Cancer

      The multi-center study will be conducted in South Korea. Data collection will be based on
      routinely scheduled and emergency visits during a 24-month surveillance period or until end
      of the study whichever occurs first after drug administration. The overall duration of the
      study will be approximately 6 years.
    
  